Ku antigen is necessary for DNA double-strand break (DSB) repair through its ability to bind DNA ends with high anity and to recruit the catalytic subunit of DNA-PK to the DSBs. Ku-de®cient cells are hypersensitive to agents causing DSBs in DNA but also to the DNA topoisomerase II (topo II) inhibitor ICRF-193, which does not induce DSBs. This suggests a new role of Ku antigen, that is independent of DSB repair by DNA-PK. Here we characterize the basis for the hypersensitivity of Ku-de®cient cells to . Chromosome condensation and segregation, which are dependent on topo II, but also the catalytic activity of topo II in late S-G2 were inhibited to a comparable extent when ICRF-193 was applied to Ku-de®cient cells or wild-type cells. However, mutant cells arrested in G2 by ICRF-193 treatment were unable to progress into M phase upon drug removal, although drug-trapped topo II complexes were removed from DNA and the two isoforms of topo II recovered their catalytic activity as in wild-type cells. The reversibility of G2 arrest was recovered by complementation of mutant cells with a human Ku86 cDNA. Notably, chromosome condensation was abnormal in Ku-de®cient cells after suppression of the G2 arrest by caeine, even in the absence of ICRF-193. These results re¯ect the involvement of Ku-antigen in the cellular response to topo II inhibition, more particularly in relieving G2 arrest caused by topo II inhibition in late S/G2 and the subsequent recovery of chromosome condensation.
Introduction
Topo II is an essential enzyme that is required for chromosome condensation and segregation in eukaryotes. It can knot or unknot DNA, as well as catenate and decatenate closed circular DNA, by passing duplex DNA through an enzyme-mediated DNA gate (reviewed in Wang, 1996; Austin and Marsh, 1998) . In mammalian cells, topo II is mainly a homodimer of two isoforms: topo IIa, a 170 kDa polypeptide that is maximally expressed during the G2 and M phases of the cell cycle, and topo IIb, a 180 kDa polypeptide that is constitutively expressed (Kimura et al., 1994; Woessner et al., 1991) . The respective roles of both isoforms are poorly understood. Topo IIa associates with the chromosome scaold and probably mediates the terminal condensation of the chromatids into 600 nm ®bers during prometaphase (Meyer et al., 1997, reviewed in Warburton and Earnshaw, 1997) . Topo II activity is also required for the segregation of the chromatids during anaphase (Uemura et al., 1987; Clarke et al., 1993; Andoh et al. 1993) . In addition to these mitotic activities, topo II has been shown to be required during late S/G2 phases in mammalian cells, by using topo II speci®c inhibitors. Topo II activity could be required to resolve DNA topological strains that are generated during DNA replication and to untangle newly replicated sister chromatids before the onset of mitosis (Downes et al., 1994; Andoh and Ishida, 1998) .
Two dierent types of drugs inhibit topo II: those that stabilize the topo II-cleaved DNA complex exempli®ed by etoposide, and catalytic inhibitors such as the bisdioxopiperazine . The covalent complex stabilized by the ®rst class of drugs plays a critical role in cell killing, most likely by the creation of double-strand breaks (DSBs) in DNA (reviewed in Chen and Liu, 1994) . DSBs activate cell cycle checkpoints, which lead to blockage of the cell cycle at particular stages, mainly at the G1-S and G2-M transition, or more dramatically to cell death by apoptosis (see Weinert, 1998 , for recent review). Bisdioxopiperazine derivatives function by trapping topo II as the closed-clamp intermediate in the presence of ATP, inhibiting the ATPase activity and catalytic turnover of the enzyme without introduction of DSBs (Patel et al., 2000; Roca et al., 1994; Tanabe et al., 1991) . Inhibition of topo II activity by leads to retardation or block of the cell cycle in G2 (Anderson and Roberge, 1996; Downes et al., 1994; Ishida et al., 1994) . Downes and collaborators have proposed a speci®c checkpoint controlling the correct decatenation of the newly replicated sister chromatids at the end of S phase to explain these eects of ICRF-193 treatment on cell cycle progression (Downes et al., 1994) . Importantly, this checkpoint appears to be absent in yeast, since temperature-sensitive topo II mutants of ®ssion or budding yeast enter an abortive mitosis when grown at the non-permissive temperature, without delay in G2 (Uemura et al., 1987; Holm et al., 1985) .
DNA-dependent protein kinase (DNA-PK) is composed of a catalytic subunit, DNA-PKcs, a 450 kDa polypeptide belonging to the PI3-kinase family, and Ku antigen, a dimer of 86 kDa and 70 kDa polypeptides that recognizes particular DNA structures, mainly DNA ends and transitions between double-stranded and single-stranded regions Morozov et al., 1994) . DNA-PK plays an important role in the cellular response to DSB. Indeed, extensive work on X-ray-sensitive cell lines and mutant mice defective in one of the subunits of DNA-PK has demonstrated unambiguously their participation in the repair of DSBs and the V(D)J recombination of immunoglobulin and T-cell receptor genes (Smith and Jackson, 1999) . The best characterized function of Ku antigen is the recruitment and the activation of DNA-PKcs (Dvir et al., 1992; Gottlieb and Jackson, 1993; reviewed in Smith and Jackson, 1999) . Nonetheless, Ku86-or Ku70-null mice display additional defects not observed in the absence of DNA-PKcs, in particular 50% smaller body size, altered growth of primary cells in culture (Nussenzweig et al., 1996; Gu et al. 1997; Gao et al., 1998) and premature senescence (Vogel et al., 1999) . These phenotypes suggest a role of Ku antigen in the cell cycle independent of DNA-PKcs.
We have shown previously that Ku-de®cient cells are hypersensitive to , which blocks topo II activity without introducing DSBs (MunÄ oz et al., 1998; Tanabe et al., 1991; Downes et al., 1994) . Ku-de®cient cells were blocked in G2 at ICRF-193 doses that had no eect on wild-type cells. Moreover, bypass of this G2 block by caeine revealed defective chromosome condensation in mutant cells, in the presence of low doses of the drug. Two putative explanations for the hypersensitivity of Ku-de®cient cells to this topo II inhibitor were the direct participation of Ku-antigen in DNA-topoisomerase II mediated activities, or alternatively a novel role of Ku in the decatenation checkpoint. Here, we show that Ku antigen is required to relieve the blockage of the cell cycle by ICRF-193 at the G2-M transition and the subsequent recovery of chromosome condensation during mitosis.
Results
Chromosome condensation and segregation are equally sensitive to topo II inhibition in Ku-deficient and wild-type cells
To analyse the possible participation of Ku-antigen in topo II mediated activities, we compared the sensitivity of wild-type and Ku86-de®cient cells to ICRF-193 during mitosis. We showed before that incubation of Ku-de®cient cells with low doses of ICRF-193 in late S/G2 leads to a G2 arrest, most probably due to a checkpoint sensitive to topo II inhibition. This arrest could be bypassed by caeine treatment, which led to entry into mitosis. Under these conditions, abnormal chromosome condensation was observed in the presence of ICRF-193 (MunÄ oz et al., 1998) . Defective condensation could thus be due to the hypersensitivity of topo II-dependent condensation activity to ICRF-193 but also to the forced bypass of the G2 checkpoint by caeine. To distinguish between these two possibilities, we examined the eect of ICRF-193 on chromosome condensation in wild-type V79B and Ku86-de®cient XR-V15B Chinese hamster ®broblasts. We applied the topo II inhibitor in early mitosis, after passage of the G2 checkpoint but before terminal condensation of the chromatids. To this end, we ®rst determined more precisely the timing of prophase and metaphase in both cell lines (Figure 1 ). Cells were synchronized in early S phase by hydroxyurea (HU) treatment and the percentage of prophase and metaphase ®gures (Figure 1 ) was determined at dierent times after HU release. Prophase ®gures appeared 5 h after HU release in both cell lines, while metaphase ®gures increased signi®cantly after 5.5 h in V79B cells and 6 h in XR-V15B cells. Strikingly, V79B cells entered metaphase more rapidly that XR-V15B cells, which could re¯ect the slower progression through G2 and early M phase in the absence of Kuantigen, as is the case in ®broblasts derived from Ku86 null mice (Nussenzweig et al., 1996) .
ICRF-193 was added 5 h after HU release to the V79B cells and 5.5 h after HU release to the XR-V15B cells. XR-V15B cells that have not reached the G2 checkpoint should arrest at 0.01 mg/ml ICRF-193 and should thus not progress into mitosis (MunÄ oz et al., 1998) . At this timepoint less than 1% of the cells Figure 1 Time course of entry into mitosis after HU release of V79B and XR-V15B cells. Early-S-phase synchronized V79B and XR-V15B cells were ®xed and stained with Hoechst 33258 at dierent times after HU-block release. The cells were incubated with nocodazole (40 ng/ml) to block the cells in prometaphase. Each time point represents the percentage of cells in prophase and metaphase as determined by¯uorescence microscopy (n=500). The experiment was repeated three times with similar results. NS: non-synchronized cells showed terminally condensed chromosomes. Therefore they could contribute at best 5% to the total population we evaluated at the end of the experiment, which contained more than 20% mitotic cells. At the maximum dose of (1 mg/ml), most mitotic V79B and XR-V15B cells showed abnormal chromosome condensation due to the inhibition of topo II (Figure 2c,f) . In contrast, after 0.01 mg/ml ICRF-193 treatment of early mitotic cells, all metaphase ®gures in XR-V15B cells (124 metaphases/500 cells) and V79B cells (137 metaphases/ 500 cells) were normal (compare Figure 2e to b) . This strongly suggests that the condensation defects observed previously at 0.01 mg/ml ICRF-193 were not due to an intrinsic hypersensitivity of topo II-dependent condensation activity in the absence of Ku86, but rather a consequence of the bypass of the G2 checkpoint sensitive to the inhibition of topo II.
Next, we analysed the other mitotic activity sensitive to the action of topo II inhibitors, chromatid segregation in early anaphase. Therefore, we blocked V79B or XR-V15B cells in prometaphase by nocodazole treatment and then released the cells in the presence of increasing doses of ICRF-193. We measured the number of cells in metaphase, anaphase or telophase at dierent time points microscopically (Figure 3a) . The transition from metaphase to anaphase was already retarded at 0.01 mg/ml ICRF-193 to a similar extent in both cell lines. This transition was completely blocked at 1 mg/ml ICRF-193 in the presence or absence of Ku-antigen. Similar data were also obtained in both cell lines at intermediate concentrations of the drug (data not shown), indicating that segregation of chromosomes in anaphase is equally sensitive to topo II inhibition in Ku-de®cient and wild-type cells. These results strongly suggest that Ku is not required for the topo II-mediated activities during mitosis and that the hypersensitivity of Ku-de®cient cells to ICRF-193 is probably due to a speci®c cellular defect related to the late S/G2 phase of the cell cycle.
No significant differences in the catalytic activity of topo II or in its sensitvity to ICRF-193 were observed between Ku-deficient and wild-type cells in late S/G2
To analyse whether the in vivo catalytic activity of topo II in late S/G2 could be altered in the Kude®cient cells, we used a semi-quantitative assay based on the ability of etoposide to block the topo II molecules engaged in a catalytic cycle at the stage when topo II is covalently linked to DNA ends (Chen et al., 1984; Burden and Oshero, 1998) . This traps catalytically-active topo II molecules on DNA in vivo, which leads to a drug-induced decrease in enzyme levels in whole cell lysates prepared in high salt (Meyer et al., 1997) . Synchronized V79B wild-type cells and mutant XR-V15B cells in late S/G2 were treated with increasing concentrations of etoposide (VP-16). Whole cell lysates were prepared in lysis buer containing 350 mM NaC1 and analysed for the two isoforms of topo II by immunoblotting. A representative experiment is shown in Figure 4a . Topo IIa and topo IIb were released eectively from the DNA at this NaC1 concentration and no major dierence in the recovery of the two isoforms was observed between both cell lines (compare lane 1 and 4 of Figure 4a ,b for quantitative data). The recovery of both isoforms of topo II decreased in response to increasing VP-16 Figure 2 Chromosome condensation in Ku-de®cient cells is not hypersensitive to ICRF-193 when the drug is applied in early mitosis. V79B (a ± c) and XR-V15B cells (d ± f) were incubated with 0.01 mg/ml (b,e) or 1 mg/ml ICRF-193 (c,f) 5 h (V79B) and 5.5 h (XR-V15B) after HU release in the presence of nocodazole (40 ng/ml). Metaphase chromosomes were prepared and stained with Hoechst 33258 dye for analysis by¯uorescence microscopy after a further 3 h incubation in the presence of the drugs. Cells incubated in the absence of ICRF-193 are shown in (a) and (d) concentrations, re¯ecting the immobilization of the enzyme molecules on DNA. Moreover, no signi®cant dierences were observed in the yield of a or b isoforms released from chromatin at the dierent VP-16 doses in wild-type and Ku-de®cient cells (Figure 4a, b) . These results indicate that the catalytic activity of both isoforms of topo II is not signi®cantly aected in vivo by the absence of Ku during late S/G2 phases.
To determine whether the topo II catalytic activity was more sensitive to inhibition by ICRF-193 in Kude®cient cells, we treated wild-type and mutant cells synchronized in late S/G2 with increasing doses of ICRF-193 and monitored the recovery of topo IIa and topo IIb in whole cell lysates. When the ICRF-193 concentration was increased, less topo II was released from the chromatin in both cell types (Figure 4c , Figure 3 Chromosome segregation in Ku-de®cient cells is not hypersensitive to ICRF-193. Cells were blocked in prometaphase by nocodazole (40 ng/ml) treatment and subsequently released in the presence of increasing doses of ICRF-193. The percentage of metaphases and anaphases+telophases was determined at dierent times after nocodazole release by microscopic inspection. The experiment was repeated three times with similar results Figure 4 Ku-de®cient and wild-type cells possess similar topo II catalytic activity and display no dierences in sensitivity to ICRF-193 in late S/G2 phases. Late S/G2 synchronized V79B wild-type or XR-V15B de®cient cells were incubated in the presence of increasing concentrations of etoposide (VP-16) for 1 h (a), or were treated with increasing concentrations of ICRF-193 for 4 h in the absence or in the presence of 200 mM VP-16 during the last hour to analyse the topo II sensitivity to . The druginduced depletion of topo IIa and topo IIb in 350 mM NaC1 whole cell lysates was then determined by immunoblotting, using 100 mg of protein per lane and speci®c antibodies for topo IIa, topo IIb and GAPDH. The intensity of the bands was quanti®ed and the values obtained for topo II were normalized to those obtained for GAPDH, and the mean + standard error obtained from three to six independent experiments is shown in (b) and (d). Each value represents the percentage of topo II recovered compared to the quantity recovered in the absence of VP-16 (b) or compare lanes 1, 3 and 5 or 7, 9 and 11, and d. This retention of topo II in chromatin is most likely explained by the formation of closed clamp complexes between topo II and DNA that are resistant to NaC1 concentrations as high as 1 M (Roca et al., 1994; Patel et al., 2000) . Interestingly, the b isoform showed a higher sensitivity towards ICRF-193 since part of this isoform was already being trapped on the DNA at 0.01 mg/ml of ICRF-193. This concentration is sucient to arrest mutant cells in G2 (compare lanes 1 and 3, or 7 and 9 in Figure 4c , and d) whereas doses of 1 mg/ml of ICRF-193, which arrest wild-type cells in G2, were required to obtain a reproducible inhibition of the a isoform (compare lane 1 and 5 or 7 and 11 in Figure 4c , and d). Furthermore, no signi®cant dierences were detected in the recovery of both topo II isoforms between wild-type and mutant cells at dierent ICRF-193 doses ( Figure 4d ).
Next we wanted to assess if the remaining topo II molecules, which were not trapped on the DNA by ICRF-193 treatment, were catalytically active. Cells synchronized in late S/G2 were incubated in the presence of dierent concentrations of ICRF-193 and etoposide was added during the last 60 min of the incubation. Comparable activities, as deduced from a similar decrease in enzyme recuperation in the whole cell extracts after etoposide treatment, were found at similar doses of ICRF-193 in both cell lines (Figure  4c,d ). Taken together, these results strongly suggest that G2 arrest observed in Ku-de®cient cells at low doses of ICRF-193 is not due to an altered catalytic activity or hypersensitivity of the enzyme to the inhibitor in S/G2.
Ku-deficient cells do not recover from G2 arrest after removal of ICRF-193
The preceding results appear to exclude any direct participation of Ku-antigen in topo II-mediated activities. Therefore we envisaged a second alternative, namely the participation of Ku antigen in G2 arrest recovery, to explain the hypersensitivity of Ku-de®cient cells. Our previous study showed that Ku is not required for G2 arrest after topo II inhibition, as both cell lines are arrested in G2 by the drug (MunÄ oz et al., 1998). We thus decided to analyse whether Ku-de®cient cells could be released from such a G2 arrest. We blocked the cell cycle using the appropriate dose of ICRF-193 in wild-type and mutant cells and followed cell cycle progression by FACscan analysis after drug removal ( Figure 5 ). Strikingly, wild-type cells, which were blocked in G2M by 1 mg/ml of ICRF-193, resumed the cell cycle normally after release, as deduced from the decrease of the proportion of cells with a DNA content of G2/M and the concomitant increase in G1 cells (data not shown). Wild-type cells were not blocked at 0.01 mg/ml, although they progressed more slowly into G1 (data not shown). In contrast, mutant cells remained in G2 even 12 h after release from 0.01 mg/ml ICRF-193 and did not progress into mitosis, as deduced from the absence of mitotic ®gures ( Figure 5 and data not shown). As shown before, Ku-de®cient cells complemented with human Ku86 cDNA (XR-V15B/C9) were not arrested at 0.01 mg/ml ICRF-193, although they progressed more slowly into M phase than wild-type cells (MunÄ oz et al., 1998) . Importantly, XR-V15B/C9 cells were arrested in G2 at 1 mg/ml ICRF-193 and, in contrast to the non-complemented mutant cells, resumed the cell cycle after removal of the drug (lower panel of Figure  5) . These results clearly demonstrate that the recovery from G2 arrest caused by topo II inhibition requires Ku-antigen.
Ku-deficient cells do not recover chromosome condensation activity after ICRF-193 removal
Ku-de®cient cells display abnormal chromosome condensation activity when the G2 checkpoint is bypassed by caeine treatment in the presence of low doses of ICRF-193 (MunÄ oz et al., 1998) . In view of the absence of condensation defects when the drug was applied in early M phase, it became interesting to analyse chromosome condensation upon a caeine-driven suppression of the G2 arrest in the absence of ICRF-193 ( Figure 6 ). We blocked wild-type or mutant cells with the appropriate dose of ICRF-193 in G2, and after its removal caeine and nocodazole were added to force entry into mitosis and block the cells in prometaphase. Chromosome condensation in wild-type (Figure 6a ). In contrast, Ku-de®cient cells did not recover normal condensation after release from 0.01 mg/ml of the drug (Figure 6c ). Both cell lines showed defective condensation when the drug was left on the cells after caeine bypass at doses of 1 mg/ml for V79B and 0.01 mg/ml for XR-V15B cells (Figure 6b,d ). These results demonstrate that, in striking contrast with wild-type cells, Ku antigen de®cient cells do not recover normal chromosome condensation after forced entry into mitosis even if the topo II inhibitor is removed from the medium.
We then assessed if the absence of dissociation of closed clamp complexes between topo II and DNA correlated with the condensation defects observed in Ku86-de®cient cells. Therefore, we evaluated the release of the enzyme from the DNA after drug removal (Figure 7) . Even after removal of 1 mg/ml ICRF-193, comparable amounts of both isoforms were released whether or not Ku-antigen was present (compare lanes 5 and 6 or 7 and 8 in Figure 7a , and c for quantitative data). Moreover, comparable topo IIa and topo IIb activities were recovered in mutant and wild-type cells after ICRF-193 removal, as determined by the etoposide assay (Figure 7b,c) . Thus, it is unlikely that a defective resolution of closed clamp complexes between topo II and DNA or a nonrecovery of catalytic activity are responsible for the condensation defects and irreversibility of the G2 arrest observed in Ku-de®cient cells after ICRF-193 release.
Discussion
We show here that the hypersensitivity of Ku-de®cient cells to ICRF-193 is not due to the direct participation of Ku antigen in topo II mediated activities. Rather, Ku is required to relieve G2 arrest caused by topo II inhibition and subsequent recovery of chromosome condensation during mitosis, indicating its participation in the cellular response to topo II inhibition in late S/G2.
Chromosome condensation in prometaphase, and chromosome segregation in anaphase, two processes dependent on topo II activity, were equally aected at low doses of ICRF-193 in wild-type and mutant cells, which suggest that Ku-de®cient cells are not hypersensitive to the topo II inhibitor during mitosis. The absence of condensation defects at the lowest dose in mutant cells is unlikely to be due to slow uptake of ICRF-193 by the cells, since addition of 0.01 mg/ml ICRF-193 led to a rapid inhibition of the transition from metaphase to anaphase. Similarly, incubation of early mitotic cells with 1 mg/ml ICRF-193 during a period as short as 15 min led to inhibition of chromosome condensation (unpublished results). Furthermore, the hypersensitivity of Ku-de®cient cells to ICRF-193 is not due to an altered catalytic activity or hypersensitivity of the enzyme to the inhibitor in S/G2. We have previously shown that the global enzymatic activity of topo II measured in nuclear extracts is similar in V79B and XR-V15B cells using an in vitro assay (MunÄ oz et al., 1998). Here we extend these ®ndings to an in vivo setting by using an etoposide-based assay that, although indirect, re¯ects the proportion of enzyme molecules actively engaged in a catalytic cycle during a well-de®ned period of the cell cycle. Thus, although we were unable to demonstrate any direct participation of Ku antigen in topo II activities during G2/M, we provide strong evidence in favour of a novel role for Ku in the cellular response to topo II inhibition. Indeed, Ku-de®cient cells were arrested in G2 at lower doses of inhibitor than wildtype cells and were unable to progress into M phase after drug removal. These defects in the G2-arrest recovery were rescued by stable complementation of Ku-de®cient cells with human Ku86 cDNA. Moreover, when Ku-de®cient cells were forced to leave the permanent G2 arrest by caeine treatment in the absence of ICRF-193, they were unable to condense their chromosomes normally, although both isoforms of topo II were released from DNA after ICRF-193 removal and recovered a catalytic activity similar to that of wild-type cells. These results indicate that Ku antigen is required to relieve G2 arrest caused by topo II inhibition and the subsequent recovery of chromosome condensation during mitosis.
To better understand how Ku helps the cell to recover from topo II inhibition, it is important to ascertain which signals induce G2 arrest upon ICRF-193 treatment. The existence of a decatenation G2 checkpoint was ®rst proposed by Downes and collaborators, and has since received independent experimental support (Downes et al., 1994; Anderson and Roberge, 1996; Andreassen et al., 1997; Kaufmann and Kies, 1998; MunÄ oz et al., 1998) . The use of bisdioxopiperazine ICRF-193 has proved to be a crucial tool in the identi®cation of this speci®c checkpoint, which can be distinguished from the wellcharacterized DNA-damage checkpoint (Tanabe et al., 1991; Downes et al., 1994) . Other groups have reported that cell cycle progression can be separated from topo II inhibition after treatment with this type of drug, raising doubts about a speci®c topo II-related G2 checkpoint Gorbsky, 1994) . This could be due, at least partially, to the use of transformed cell lines in which checkpoint controls might be dysfunctional. In this respect, it is notable that diploid human ®broblasts and mouse embryo ®broblasts were eectively blocked in G2 by ICRF-193 (Kaufmann and Kies, 1998; our unpublished results) . Although ICRF-193 was reported not to induce DSBs in DNA it was important to exclude the creation of such lesions as a secondary consequence of topo II inhibition, which would be the most obvious explanation for the hypersensitivity of Ku-de®cient cells to any topo II inhibitors. We have previously shown that no DSBs were detected at doses of ICRF-193 which induced a maximal arrest in G2, whereas suboptimal doses of the radiomimetic drug, bleomycine, led to the formation of clearly detectable DSBs. Moreover, cell lines defective in DNA-PKcs, an essential element in the repair of DSBs, were not hypersensitive to ICRF-193 (MunÄ oz et al., 1998) . Similar evidence was recently obtained in yeast cells expressing human topo IIa, where cell killing by ICRF-193 was not enhanced by mutations in the RAD52 pathway necessary for recombinational repair of DSBs (Jensen et al., 2000) .
One possible hypothesis to explain the hypersensitivity of Ku-de®cient cells to ICRF-193 is that Kuantigen is involved in the detection and subsequent elimination of closed clamp complexes formed between topo II and DNA during the G2 phase. If this were the case, these structures should accumulate at low doses of ICRF-193 in the absence of Ku. Our results contradict this hypothesis, since we observed no signi®cant dierences between both cell lines in the recovery of both isoforms of topo II in response to dierent doses of ICRF-193, and these proteins were normally released from the DNA after removal of the drug.
Which other signal could be responsible for G2 arrest? It is unlikely that complete decatenation of the sister chromatids is required for passage into mitosis, nor that intertwined chromatids function as a signal Figure 7 Closed clamp complexes formed between topo II and DNA are dissociated and the topo II catalytic activity is recovered after ICRF-193 removal in both V79B and XR-V15B cells. The recovery of a and b isoforms of topo II from V79B and XR-V15B cells was analysed in whole cell extracts obtained in 350 mM NaC1 buer from: (a) G2-synchronized cells (lane 1 and 2), G2-arrested cells by treatment with 1 mg/ml ICRF-193 (lanes 3 and 4) and similar cells incubated in the absence of the drug for 1 h (lanes 5 and 6) or 2 h (lanes 7 and 8). (b) G2-arrested cells by 1 mg/ml ICRF-193 treatment for 4 h (lanes 1, 2, 7 and 8) and similar cells released from the drug for 1 h (lanes 3, 4, 9 and 10) or 2 h (lanes 5, 6, 11 and 12) were incubated in the absence or in the presence of 200 mM VP-16 during the last 30 min. 100 mg of whole cell extract was loaded per lane, and after blotting the membrane was probed with antibodies against topo IIa, topo IIb and GAPDH. The results were quanti®ed and the mean+ standard error from three or four dierent experiments is shown in (c). Each determination represents the percentage of topo II recovered compared to the amount recovered in G2-synchronized V79B or XR-V15B cells for checkpoint activation. Indeed, it has been argued that chromatids remain intertwined during mitosis and are completely untangled only at anaphase (Holm, 1994) . Top II was postulated to resolve the topological strain that is created when two replication forks meet during DNA replication (Sundin and Varshavski, 1980; DiNardo et al., 1984) . Thus, it is more likely that topo II inhibition at the end of DNA replication disrupts its completion, generating torsional stress in DNA that could lead to abnormal DNA conformations and thereby constitute a signal for cell cycle arrest. Ku-antigen could then be involved in the resolution of these abnormal DNA conformations.
In this regard, it has been proposed recently that helicases can cooperate with topo II and even topoisomerases of class I, such as topo III, to bring about topological changes which require DNA strand passage (Duguet, 1997; Wu et al., 1999) . It has been shown that Ku has an intrinsic DNA helicase activity in vitro (Tuteja et al., 1994 ). An alternative mechanism could be provided by the recently demonstrated physical and functional interaction between Ku and WRN, the RecQ-like helicase mutated in Werner syndrome (WS) (Cooper et al., 2000) . WS is characterized by genetic instability and premature senescence and several lines of evidence point to a role of WRN in resolving aberrant DNA structures that arise from DNA replication, recombination and/or repair (Shen and Loeb, 2000) . Accordingly, it is tempting to propose that Ku-antigen and WRN could compensate for topo II inhibition in wild-type cells by cooperating with other topoisomerases. In this scenario, the hypersensitivity of Ku-de®cient cells to topo II inhibition could be ascribed to the accumulation of abnormal DNA conformations at the end of S phase and subsequent G2 arrest.
One ®nal, important point in this work is that Kude®cient cells are unable to condense their chromosomes upon forced release from the ICRF-193-induced G2 arrest by caeine treatment. In contrast, normal condensation was observed after bypass of G2 arrest induced by bleomycin, a radiomimetic drug (MunÄ oz et al., 1998) . These observations permit the dierentiation of G2 arrest induced by topo II inhibition and G2 arrest induced by DNA damage. Topo II inhibition could lead to incompletely replicated DNA and abnormal DNA structures, which could be an inappropriate substrate for chromosome condensation. In this situation the operation of a G2 checkpoint would be crucial to ensure that DNA is correctly organized before the onset of mitosis.
Materials and methods

Cell lines and drugs
V79B wild-type and XR-V15B Ku86 de®cient cell lines, derived from V79 Chinese hamster ®broblasts, were kindly provided by MZ Zdzienicka (Leiden University, Leiden, The Netherlands) (Errami et al., 1996; Zdzienicka et al., 1988) . Stable transfectant XR-V15B/C9, obtained by transfection of XR-V15B cells with the human Ku86 cDNA, has been previously characterized (MunÄ oz et al., 1998) . All cell lines are grown in Dulbecco's modi®ed Eagle's medium supplemented with 10% foetal calf serum, 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (0.1 mg/ml). Cells were maintained at 378C under a 5% CO 2 humidi®ed atmosphere.
ICRF-193 was generously provided by AM Creighton (St Bartholomew's Hospital Medical College, London, UK) and was dissolved at 1 mg/ml in dimethyl sulphoxide. Bleomycin (purchased from Roger Ballon, France) was dissolved at 10 mg/ml in sterile water. Nocodazole was dissolved at 1 mg/ ml in dimethyl sulphoxide. Etoposide was resuspended as a 10 mg/ml stock solution in dimethyl sulphoxide and hydroxyurea (HU) was dissolved at 200 mM in sterile water (Sigma-Aldrich, St-Louis, Missouri, USA). All stock solutions were stored at 7208C. Caeine was freshly prepared at 100 mM in sterile phosphate-buered saline (PBS) pH 7.4.
Cell synchronization and drug treatment
Early-S-phase cell populations were obtained by blocking DNA synthesis with HU. Brie¯y, 6.5610 5 cells were seeded in 60 mm-diameter dishes and treated with 1 mM HU for 16 h. To determinate the prophase and metaphase timing, cells were liberated from the HU block by rinsing for 30 min and then cultivated in drug-free medium for dierent times in the presence of nocodazole (40 ng/ml) which was added 3.5 h after HU release. The cells were then ®xed with methanolacetic acid (3 : 1) solution and stained with Hoechst 33258. The percentage of cells in prophase (as indicated by the presence of the pre-condensed chromosomes) and metaphase (as indicated by the lack of the nuclear membrane and totally condensed chromosomes) was determined by microscopic inspection, counting at least 500 cells for each plate.
To determine the eect of ICRF-193 on chromosome condensation, dierent concentrations of the drug were added to the medium 5 h (V79B) or 5.5 h (XR-V15B) after HU block release. Cells were incubated in these conditions for 3 h in the presence of nocodazole (40 ng/ml) in order to block the cells in metaphase. At the end of the treatment the mitotic cells were recovered by very gentle trypsinization (1 min) and metaphase chromosomes were prepared as previously described (MunÄ oz et al., 1998) .
To analyse the eect of ICRF-193 on the progression from metaphase to anaphase, early-S phase synchronized cells were released from HU block and incubated in drug-free medium for 3 h. At this point nocodazole (40 ng/ml) was added to the medium and the cell culture was continued for 4 h to block the cells in prometaphase. At the end of this treatment, the nocodazole was eliminated and the cells were rinsed with drug-free Dulbecco's Modi®ed Eagle's Medium (DMEM) and incubated in normal medium or medium containing ICRF-193. Cells were incubated for 10, 15, 20, 25, 30 or 45 mins, then ®xed with methanol : acetic acid (3 : 1) solution for 10 min at room temperature and stained with Hoechst 33258. The percentage of cells in metaphase or anaphase and telophase was determined by microscopic inspection, counting at least 100 cells for each plate. We considered cells in metaphase when the sister chromatids were still linked together, and in anaphase when they were clearly separated.
To analyse the reversibility of the ICRF-193-induced G2-arrest, dierent concentrations of ICRF-193 were added to the cells 3.5 h after release from HU block (at that time 50% of the cells were in late S and 50% of the cells were in G2 phase). The cells were incubated in these conditions for 4 h in order to induce a G2-arrest. Next, ICRF-193 was removed from the medium and the cells were subsequently rinsed with fresh medium and the cell culture was continued in a drugfree medium for the times indicated in the legend of the ®gures. To quantify the cells at dierent stages of the cell cycle, cells were harvested and the DNA was stained with propidium iodide solution (0.025 mg of propidium iodide per ml, 0.1% sodium citrate, 0.1 mg of RNase A per ml, 0.1% Triton X-100). The DNA content of the cells was analysed by FACscan (Becton Dickinson, San Jose, CA, USA).
To analyse the recovery of the chromosome condensation activity after release of G2 arrest, the cells induced to G2-arrest by ICRF-193 treatment were incubated in the absence or presence of ICRF-193, nocodazole (40 ng/ml) and caeine (2 mM) for 2 h. Then, the mitotic cells were recovered by very gentle trypsinization and metaphase chromosomes were prepared as described in MunÄ oz et al., (1998).
Assay of DNA topoisomerase II in vivo activity G2 phase synchronized cells (4.5 h after HU block release) and late S/G2 phase synchronized cells treated with ICRF-193 for 4 h were cultured with or without etoposide (VP-16) for the last hour. Cells blocked in G2 by 1 mg/ml of ICRF-193 and released for 1 or 2 hours were cultured with or without etoposide (VP-16) for the last 30 min. At the end of the dierent treatments the cells were recovered by placing the dishes on ice, rinsing twice with PBS at 48C and scraping in cold PBS. Cell suspensions were centrifuged at 1200 r.p.m. for 5 min at 48C and chilled at 7808C. Cells were resuspended in cold lysis buer (50 mM Tris-HCl pH 8.0, 5 mM EDTA, 350 mM NaC1, 0.5% NP-40 (vol/vol) containing protease inhibitors (5 mg aprotinin, 5 mg leupeptin and 10 mg pepstatin per ml, 1 mM benzamidine, 2 mM phenylmethylsufonyl¯uoride (PMSF) and 30 mM NaF). Cells were lysed on ice for 30 min and centrifuged at 13 000 r.p.m. for 5 min at 48C. Protein concentration in the supernatant was determined by the bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). Proteins were separated by SDSpolyacrylamide gel electrophoresis (PAGE) and transferred electrophoretically to polyvinylidene di¯uoride membranes (Millipore, Bedford, MA, USA) at 0.8 mA/cm 2 for 1 h in 25 mM Tris-HCl-192 mM glycine-20% methanol. The antibodies used in the immunostaining were: an anti-DNA topoisomerase IIa polyclonal antibody (Bio Trends, KoÈ ln, Germany), the anti-DNA topoisomerase IIb monoclonal antibody 3H10, kindly provided by A Kikuchi (Nagoya University School of Medicine, Nagoya, Japan) (Kimura et al., 1996) and an anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) polyclonal antibody (gift of JM Blanchard). Peroxidase-labelled goat secondary antibodies (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and enhanced chemiluminiscence assay were used to detect the antibodies. The ®lms were scanned and the signal intensity of the bands was quanti®ed using NIH Image 1.61/68K (http:// rsb.info.nig.gov/nih-image/).
